Alzamend Neuro (NASDAQ:ALZN – Get Free Report) and Aerovate Therapeutics (NASDAQ:AVTE – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, dividends, risk, analyst recommendations, institutional ownership, valuation and earnings.
Risk & Volatility
Alzamend Neuro has a beta of 0.16, suggesting that its stock price is 84% less volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500.
Valuation & Earnings
This table compares Alzamend Neuro and Aerovate Therapeutics”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alzamend Neuro | N/A | N/A | -$8.77 million | ($2.90) | -0.50 |
| Aerovate Therapeutics | N/A | N/A | -$75.52 million | ($1.70) | -13.65 |
Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Alzamend Neuro, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current recommendations and price targets for Alzamend Neuro and Aerovate Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alzamend Neuro | 1 | 0 | 1 | 0 | 2.00 |
| Aerovate Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
Alzamend Neuro currently has a consensus price target of $28.00, suggesting a potential upside of 1,817.81%. Given Alzamend Neuro’s stronger consensus rating and higher probable upside, analysts clearly believe Alzamend Neuro is more favorable than Aerovate Therapeutics.
Profitability
This table compares Alzamend Neuro and Aerovate Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Alzamend Neuro | N/A | -277.74% | -200.07% |
| Aerovate Therapeutics | N/A | -90.19% | -77.47% |
Insider and Institutional Ownership
49.6% of Alzamend Neuro shares are owned by institutional investors. 1.4% of Alzamend Neuro shares are owned by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Alzamend Neuro beats Aerovate Therapeutics on 6 of the 11 factors compared between the two stocks.
About Alzamend Neuro
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
About Aerovate Therapeutics
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Receive News & Ratings for Alzamend Neuro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alzamend Neuro and related companies with MarketBeat.com's FREE daily email newsletter.
